Activation of
retinoid X receptors induces apoptosis in HL-60 cell lines.
Studies Indicate that Activating
Retinoid X Receptors Plays Key
Targretin is promising for CTCL patients--and perhaps for psoriasis, diabetes, and cancer patients as well--because it represents the first agent in a novel class of drugs called rexinoids that bind to the
retinoid X receptors (RXRs).
The harmful effects of the chemical on the liver and the nervous and immune systems in mammals are well known, but its powerful effects on the cellular components known as
retinoid X receptors (RXRs) in a range of species are a recent discovery.
Targretin is the world's only approved drug that binds selectively to
retinoid X receptors (RXRs).
The preclinical results announced today suggest that in addition to its other mechanisms of action, Targretin also acts to sensitize cancer cells to chemotherapy at the molecular level through its selective activation of
retinoid X receptors.
The authors note that Targretin caused fewer side effects than other retinoids because it is the only drug that binds selectively to
retinoid X receptors.
Targretin binds selectively to
retinoid X receptors.
Targretin, also known as LGD1069 (bexarotene), a synthetic retinoid analogue discovered by Ligand scientists, selectively activates a subclass of retinoid receptors called
Retinoid X Receptors (RXR), which play an important role in the control of cellular functions.
Discovered by Ligand scientists, Targretin (pronounced tar-GRET-tin), generically known as bexarotene, is a synthetic compound representing a novel class of retinoids that selectively activate
retinoid X receptors (RXRs).
Discovered by Ligand scientists, Targretin (pronounced tar-GRET-tin), generically known as bexarotene, is a synthetic compound representing a novel subclass of retinoids that selectively activate
retinoid X receptors (RXRs).
